The endothelin system and endothelin receptor antagonists

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

There is increasing evidence that endothelin receptor blockade and, in particular, ETA receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection. Recent findings: Recent clinical trials using ETA receptor blockade in treating proteinuria and chronic kidney disease as wellas atherosclerosis show great promise; however, adverse effects are still problematic. Summary: Endothelin receptor blockade is associated with a significant attenuation of proteinuria and these effectsare mediated in part via inhibition of inflammatory and oxidative stress related pathways as well profibrotic pathways. The addition of ETA receptor blockade to currently established therapies such as angiotensinconverting enzyme inhibitors or angiotensin receptor blockers may result in additional or synergisticrenoprotection and vasculoprotection in hypertension and, in particular, in the context of diabetes.
Original languageEnglish
Pages (from-to)66 - 71
Number of pages6
JournalCurrent Opinion in Nephrology and Hypertension
Volume21
Issue number1
DOIs
Publication statusPublished - 2012

Cite this

@article{9ca990f9187a45d1a76df2755ec11351,
title = "The endothelin system and endothelin receptor antagonists",
abstract = "There is increasing evidence that endothelin receptor blockade and, in particular, ETA receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection. Recent findings: Recent clinical trials using ETA receptor blockade in treating proteinuria and chronic kidney disease as wellas atherosclerosis show great promise; however, adverse effects are still problematic. Summary: Endothelin receptor blockade is associated with a significant attenuation of proteinuria and these effectsare mediated in part via inhibition of inflammatory and oxidative stress related pathways as well profibrotic pathways. The addition of ETA receptor blockade to currently established therapies such as angiotensinconverting enzyme inhibitors or angiotensin receptor blockers may result in additional or synergisticrenoprotection and vasculoprotection in hypertension and, in particular, in the context of diabetes.",
author = "Jandeleit-Dahm, {Karin Agnes Maria} and Anna Watson",
year = "2012",
doi = "10.1097/MNH.0b013e32834dde48",
language = "English",
volume = "21",
pages = "66 -- 71",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

The endothelin system and endothelin receptor antagonists. / Jandeleit-Dahm, Karin Agnes Maria; Watson, Anna.

In: Current Opinion in Nephrology and Hypertension, Vol. 21, No. 1, 2012, p. 66 - 71.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The endothelin system and endothelin receptor antagonists

AU - Jandeleit-Dahm, Karin Agnes Maria

AU - Watson, Anna

PY - 2012

Y1 - 2012

N2 - There is increasing evidence that endothelin receptor blockade and, in particular, ETA receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection. Recent findings: Recent clinical trials using ETA receptor blockade in treating proteinuria and chronic kidney disease as wellas atherosclerosis show great promise; however, adverse effects are still problematic. Summary: Endothelin receptor blockade is associated with a significant attenuation of proteinuria and these effectsare mediated in part via inhibition of inflammatory and oxidative stress related pathways as well profibrotic pathways. The addition of ETA receptor blockade to currently established therapies such as angiotensinconverting enzyme inhibitors or angiotensin receptor blockers may result in additional or synergisticrenoprotection and vasculoprotection in hypertension and, in particular, in the context of diabetes.

AB - There is increasing evidence that endothelin receptor blockade and, in particular, ETA receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection. Recent findings: Recent clinical trials using ETA receptor blockade in treating proteinuria and chronic kidney disease as wellas atherosclerosis show great promise; however, adverse effects are still problematic. Summary: Endothelin receptor blockade is associated with a significant attenuation of proteinuria and these effectsare mediated in part via inhibition of inflammatory and oxidative stress related pathways as well profibrotic pathways. The addition of ETA receptor blockade to currently established therapies such as angiotensinconverting enzyme inhibitors or angiotensin receptor blockers may result in additional or synergisticrenoprotection and vasculoprotection in hypertension and, in particular, in the context of diabetes.

UR - http://www.ncbi.nlm.nih.gov/pubmed/22123210

U2 - 10.1097/MNH.0b013e32834dde48

DO - 10.1097/MNH.0b013e32834dde48

M3 - Article

VL - 21

SP - 66

EP - 71

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 1

ER -